PEDMARQSI (Norgine Pty Ltd)
Product name
PEDMARQSI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
148 (255 working days)
Active ingredients
sodium thiosulfate anhydrous
Registration type
EOI
Indication
Pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, nonmetastatic, solid tumours.